EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Efficacy and Safety of Ensitrelvir for Asymptomatic or Mild COVID‐19: An Exploratory Analysis of a Multicenter, Randomized, Phase 2b/3 Clinical Trial

Norio Ohmagari, Hiroshi Yotsuyanagi, Yohei Doi, Masaya Yamato, Takumi Imamura, Hiroki Sakaguchi, Hideki Yamanaka, Ryosuke Imaoka, Akimasa Fukushi, Genki Ichihashi, Takao Sanaki, Yuko Tsuge und 2 weitere

Influenza and Other Respiratory Viruses · 2024

DOI: 10.1111/irv.13338 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Norio Ohmagari und 13 weiteren Autor:innen. Beteiligte Einrichtung: Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19 Drug Treatment, COVID-19. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shionogi & Co., Ltd., Ministry of Health, Labour and Welfare, EPS Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This phase 2b/3, randomized, placebo‐controlled trial explored the efficacy and evaluated the safety of ensitrelvir. This trial involved individuals with asymptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and patients with mild symptoms of coronavirus disease 2019 (COVID‐19).

Methods

The trial was conducted at 57 medical institutions in Japan, South Korea, and Vietnam (study period: January 6–August 14, 2022). Eligible participants were randomized (1:1:1) to the ensitrelvir 125‐mg, ensitrelvir 250‐mg, or placebo group, received the allocated intervention orally, and were followed up until Day 28. Participants self‐rated the severity of 14 typical COVID‐19 symptoms and recorded the data in an electronic diary.

Results

In total, 572 participants (194, 189, and 189 in the ensitrelvir 125‐mg, ensitrelvir 250‐mg, and placebo groups, respectively) were included in the intention‐to‐treat population. Ensitrelvir 125‐mg group observed a 77% reduction in the risk of developing any of the 14 COVID‐19 symptoms or fever and a 29% reduction in the risk of worsening of such symptoms or fever versus placebo (statistically nonsignificant). The viral RNA, viral titer, and time to infectious viral clearance observed a statistically significant decrease versus placebo. Most treatment‐related adverse events (TEAEs) were mild to moderate in severity, and the most common TEAE observed across groups was a decrease in high‐density lipoprotein.

Conclusions

Our exploratory results suggest a potential reduction in the risk of development or worsening of COVID‐19 symptoms with ensitrelvir. Ensitrelvir showed antiviral efficacy and was well tolerated. Trial Registration: Japan Registry of Clinical Trials identifier: jRCT2031210350.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19 Drug TreatmentCOVID-19HumansMaleFemaleAdultMiddle AgedAntiviral AgentsTreatment OutcomeAsymptomatic InfectionsVietnamJapanAgedRepublic of KoreaYoung AdultIndazolesTriazinesTriazoles

Stichwörter der Autor:innen

COVID‐19 drug treatmentasymptomatic infectionscontrolled clinical trialensitrelvirpostexposure prophylaxis

Substanzen

Antiviral AgentsensitrelvirIndazolesTriazinesTriazoles

Autor:innen und Institutionen

  • Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Departments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Japan.
  • Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Department of General Medicine and Infectious Diseases, Rinku General Medical Center, Izumisano, Japan.
  • Drug Development and Regulatory Science Division, Shionogi & Co., Ltd, Osaka, Japan.

ORCID-Profile: Takeki Uehara

Förderung

  • Shionogi & Co., Ltd.
  • Ministry of Health, Labour and Welfare
  • EPS Corporation
  • Shionogi

Zitieren

APA

Ohmagari, N., Yotsuyanagi, H., Doi, Y., Yamato, M., Imamura, T., Sakaguchi, H., Yamanaka, H., Imaoka, R., Fukushi, A., Ichihashi, G., Sanaki, T., Tsuge, Y., Uehara, T., & Mukae, H. (2024). Efficacy and Safety of Ensitrelvir for Asymptomatic or Mild COVID‐19: An Exploratory Analysis of a Multicenter, Randomized, Phase 2b/3 Clinical Trial. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.13338

Vancouver

Ohmagari N, Yotsuyanagi H, Doi Y, Yamato M, Imamura T, Sakaguchi H, et al. Efficacy and Safety of Ensitrelvir for Asymptomatic or Mild COVID‐19: An Exploratory Analysis of a Multicenter, Randomized, Phase 2b/3 Clinical Trial. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.13338

BibTeX
@article{Ohmagari2024,
  author = {Ohmagari, Norio and Yotsuyanagi, Hiroshi and Doi, Yohei and Yamato, Masaya and Imamura, Takumi and Sakaguchi, Hiroki and Yamanaka, Hideki and Imaoka, Ryosuke and Fukushi, Akimasa and Ichihashi, Genki and Sanaki, Takao and Tsuge, Yuko and Uehara, Takeki and Mukae, Hiroshi},
  title = {Efficacy and Safety of Ensitrelvir for Asymptomatic or Mild COVID‐19: An Exploratory Analysis of a Multicenter, Randomized, Phase 2b/3 Clinical Trial},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2024},
  doi = {10.1111/irv.13338}
}
Kostenlos starten →